Rhythm Pharmaceuticals (RYTM)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Key Insights
Critical company metrics and information
Share Price
$60.08Market Cap
$3.69 BillionTotal Outstanding Shares
61.46 Million SharesTotal Employees
226Dividend
No dividendIPO Date
October 5, 2017SIC Description
Pharmaceutical PreparationsHomepage
http://www.rhythmtx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow | $-113.54 Million |
Net Cash Flow From Investing Activities, Continuing | $-90.82 Million |
Net Cash Flow From Financing Activities | $2.49 Million |
Net Cash Flow From Financing Activities, Continuing | $2.49 Million |
Net Cash Flow From Operating Activities, Continuing | $-25.21 Million |
Net Cash Flow From Operating Activities | $-25.21 Million |
Net Cash Flow, Continuing | $-113.54 Million |
Net Cash Flow From Investing Activities | $-90.82 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $-44.97 Million |
Basic Average Shares | $61.22 Million |
Gross Profit | $29.42 Million |
Revenues | $33.25 Million |
Net Income/Loss Attributable To Parent | $-43.64 Million |
Selling, General, and Administrative Expenses | $35.38 Million |
Benefits Costs and Expenses | $77.24 Million |
Diluted Average Shares | $61.22 Million |
Basic Earnings Per Share | $0.73 |
Cost Of Revenue | $3.83 Million |
Income/Loss From Continuing Operations After Tax | $-43.64 Million |
Research and Development | $37.93 Million |
Income Tax Expense/Benefit | $344000.00 |
Income/Loss From Continuing Operations Before Tax | $-43.98 Million |
Net Income/Loss | $-43.64 Million |
Operating Income/Loss | $-43.88 Million |
Preferred Stock Dividends And Other Adjustments | $1.33 Million |
Operating Expenses | $73.31 Million |
Nonoperating Income/Loss | $100000.00 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $1.33 Million |
Costs And Expenses | $77.14 Million |
Diluted Earnings Per Share | $0.73 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Noncurrent Assets | $23.23 Million |
Other Current Liabilities | $92.72 Million |
Inventory | $13.89 Million |
Other Current Assets | $28.06 Million |
Current Assets | $340.34 Million |
Cash | $298.39 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Other Non-current Assets | $22.43 Million |
Liabilities And Equity | $363.57 Million |
Noncurrent Liabilities | $113.27 Million |
Equity Attributable To Parent | $11.21 Million |
Fixed Assets | $801000.00 |
Liabilities | $210.88 Million |
Temporary Equity Attributable To Parent | $141.48 Million |
Equity | $11.21 Million |
Accounts Payable | $4.89 Million |
Current Liabilities | $97.61 Million |
Temporary Equity | $141.48 Million |
Assets | $363.57 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.